Abstract
Subjects at risk of infection with human immunodeficiency virus (HIV) are also at high risk of acute and chronic hepatitis B virus (HBV) infection. HIV is associated with higher HBV viraemia and with the risk of HBV reactivation, chronic active HBV infection, cirrhosis and death. Therefore, hepatitis B vaccination is recommended for all HIV-infected subjects lacking prior immunity. However, the immune response to hepatitis B vaccine is frequently suboptimal in this population. High CD4+ cell counts and low HIV viraemia are well known factors associated with a better rate of response. Moreover, higher hepatitis B vaccine doses and/or prolongation of the vaccination schedule, as implemented for patients with immune deficiencies other than HIV, may be considered. New vaccination cycles should be considered if post-vaccination titers of antibodies to hepatitis B surface antigen are < 10 mIU/mL ( < 10 UI/L). The immunization of all young and middle-aged adults appears to be the most useful strategy to protect all patient-populations at high risk of sexually transmitted diseases.
Keywords: Hepatitis B Vaccination, human immunodeficiency virus (HIV), hepatitis B virus (HBV), immune deficiencies, antibodies, sexually transmitted diseases, HIV-infected subjects
Current Molecular Pharmacology
Title: Hepatitis B Vaccination in HIV-Infected Subjects
Volume: 1
Author(s): Marco Bongiovanni and Maddalena Casana
Affiliation:
Keywords: Hepatitis B Vaccination, human immunodeficiency virus (HIV), hepatitis B virus (HBV), immune deficiencies, antibodies, sexually transmitted diseases, HIV-infected subjects
Abstract: Subjects at risk of infection with human immunodeficiency virus (HIV) are also at high risk of acute and chronic hepatitis B virus (HBV) infection. HIV is associated with higher HBV viraemia and with the risk of HBV reactivation, chronic active HBV infection, cirrhosis and death. Therefore, hepatitis B vaccination is recommended for all HIV-infected subjects lacking prior immunity. However, the immune response to hepatitis B vaccine is frequently suboptimal in this population. High CD4+ cell counts and low HIV viraemia are well known factors associated with a better rate of response. Moreover, higher hepatitis B vaccine doses and/or prolongation of the vaccination schedule, as implemented for patients with immune deficiencies other than HIV, may be considered. New vaccination cycles should be considered if post-vaccination titers of antibodies to hepatitis B surface antigen are < 10 mIU/mL ( < 10 UI/L). The immunization of all young and middle-aged adults appears to be the most useful strategy to protect all patient-populations at high risk of sexually transmitted diseases.
Export Options
About this article
Cite this article as:
Bongiovanni Marco and Casana Maddalena, Hepatitis B Vaccination in HIV-Infected Subjects, Current Molecular Pharmacology 2008; 1 (3) . https://dx.doi.org/10.2174/1874467210801030191
DOI https://dx.doi.org/10.2174/1874467210801030191 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TRPV4 Agonists and Antagonists
Current Topics in Medicinal Chemistry Development of New Immunotherapies for Japanese Cedar Pollinosis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Intravenous Application of Allogenic Peripheral Blood-Derived Mesenchymal Stem Cells: A Safety Assessment in 291 Equine Recipients
Current Stem Cell Research & Therapy Neuroprotection Abilities of Cytosolic Phospholipase A2 Inhibitors in Kainic acid-induced Neurodegeneration
Current Drug Targets - Cardiovascular & Hematological Disorders Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids
Current Drug Delivery Research Advancements in Porcine Derived Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Interaction and Reaction of the Antioxidant Mn<sup>III</sup> [Meso-Tetrakis(4-NMethyI Pyridinium) Porphyrin] with the Apoptosis Reporter Lipid Phosphatidylserine
Current Physical Chemistry The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspectives
Current Diabetes Reviews Spirulina in Health Care Management
Current Pharmaceutical Biotechnology Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Infectious Disorders - Drug Targets Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Current Perspectives in Prostate Cancer Vaccines
Anti-Cancer Agents in Medicinal Chemistry Induced Pluripotency and Gene Editing in Fanconi Anemia
Current Gene Therapy Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives
Mini-Reviews in Medicinal Chemistry Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine The Dual Role of Nitric Oxide in Glioma
Current Pharmaceutical Design Cells Under Pressure – Treatment of Eukaryotic Cells with High Hydrostatic Pressure, from Physiologic Aspects to Pressure Induced Cell Death
Current Medicinal Chemistry C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry